{"id":1040,"slug":"韓国-幹細胞-豊胸-で出てくる幹細胞入り脂肪注入は-普通の脂肪注入と何が違うのですか","question":"「韓国 幹細胞 豊胸」で出てくる幹細胞入り脂肪注入は、普通の脂肪注入と何が違うのですか？","intent":"comparison","language":"ja","url":"https://worldwiki.io/q/韓国-幹細胞-豊胸-で出てくる幹細胞入り脂肪注入は-普通の脂肪注入と何が違うのですか","entity":{"slug":"breast-fat-grafting","name":"Breast Fat Grafting","url":"https://worldwiki.io/entity/breast-fat-grafting"},"answer":{"short_answer":"採取した脂肪からSVF（間質血管細胞群）や脂肪由来幹細胞を取り出し、注入する脂肪に加えて生着を高めようとする方法で、cell-assisted lipotransfer（CAL）などと呼ばれます。ただし本項の出典の範囲では、通常の脂肪注入に対する優位性を示す決定的なデータは示されていません。米国ではSVFを扱う製品は自家脂肪そのものより厳しい審査対象とされ、FDAは未承認の幹細胞治療について注意喚起も出しています。追加料金を払う前に、何をどう加えるのか、その根拠となる論文は独立したものかを確認してください。","detailed_answer":"<p>脂肪から分離したSVF（stromal vascular fraction）や脂肪由来幹細胞を併用する手技は、システマティックレビューの対象になっています（出典[13][14]）。韓国のクリニックによる報告もありますが、その一部は施術提供側の医師自身が著者である研究（provider-affiliated）であり、独立した検証とは区別して読む必要があります（出典[11][16]）。</p><p>規制面では、米国FDAは同一手術内で採取・再注入する自家脂肪について2017年11月のガイダンスで市販前承認を不要としつつ、SVF製品にはより厳格な審査を適用しています（出典[6][7]）。FDAは未承認の幹細胞治療に関する消費者向け警告も公表しています（出典[17]）。日本国内で細胞加工を伴う医療を行う場合の手続きは厚生労働省の所管ですが、本項の出典はそれを扱っていません。</p><p>本項の出典からは、「幹細胞を足せば定着率が確実に上がる」とは言えません。追加費用の対価として何が提供されるのかを書面で確認するのが現実的です。</p>","format":"paragraph","confidence":55,"verified_at":null,"updated_at":"2026-09-20 17:11:10"},"sources":[{"id":274,"title":"Safety and Regulation of Fat Grafting (Raj S, Abu-Ghname A, Davis MJ, Izaddoost SA, Winocour SJ; Semin Plast Surg 2020;34(1):59–64)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7023970/","publisher":"Seminars in Plastic Surgery (Thieme) via PubMed Central","type":"journal","accessed_at":"2026-09-19 18:00:35"},{"id":132,"title":"Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/same-surgical-procedure-exception-under-21-cfr-127115b-questions-and-answers-regarding-scope","publisher":"US Food and Drug Administration (CBER)","type":"government","accessed_at":"2026-09-18 18:00:56"},{"id":27,"title":"A Study on Breast Augmentation Using Fat Grafting With Stromal Vascular Fraction (Shin DJ, Ann Plast Surg 2023;90(4):380-384)","url":"https://pubmed.ncbi.nlm.nih.gov/36881737/","publisher":"Annals of Plastic Surgery","type":"academic","accessed_at":"2026-09-19 18:00:57"},{"id":23,"title":"Cell-Assisted Lipotransfer: A Systematic Review of its Efficacy","url":"https://pubmed.ncbi.nlm.nih.gov/37608190/","publisher":"Aesthetic Plastic Surgery (2024)","type":"academic","accessed_at":"2026-09-19 18:01:02"},{"id":24,"title":"Comparison of the Efficacy and Safety of Cell-Assisted Lipotransfer and Platelet-Rich Plasma Assisted Lipotransfer","url":"https://pubmed.ncbi.nlm.nih.gov/33845642/","publisher":"Cell Transplantation (2021)","type":"academic","accessed_at":"2026-09-19 18:01:01"},{"id":20,"title":"Safety profile of autologous adipose-derived stromal vascular fraction in clinical use: an exhaustive literature review","url":"https://pubmed.ncbi.nlm.nih.gov/41618435/","publisher":"Stem Cell Research & Therapy (2026)","type":"academic","accessed_at":"2026-09-19 18:01:00"},{"id":28,"title":"Breast Augmentation by Fat Transplantation With Adipose-Derived Stem/Stromal Cells (Shin DJ, Aesthet Surg J Open Forum 2020)","url":"https://pubmed.ncbi.nlm.nih.gov/33791627/","publisher":"Aesthetic Surgery Journal Open Forum","type":"academic","accessed_at":"2026-09-19 18:00:58"},{"id":2,"title":"FDA Warns About Stem Cell Therapies","url":"https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies","publisher":"U.S. Food and Drug Administration","type":"government","accessed_at":"2026-09-15 01:35:59"}],"published_at":"2026-09-20 08:11:10"}